Cancer Chemoprevention Using Nanotechnology-Based Approaches

Cancer research in pursuit of better diagnostic and treatment modalities has seen great advances in recent years. However, the incidence rate of cancer is still very high. Almost 40% of women and men are diagnosed with cancer during their lifetime. Such high incidence has not only resulted in high m...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 11; p. 323
Main Authors Desai, Preshita, Thumma, Naga Jyothi, Wagh, Pushkaraj Rajendra, Zhan, Shuyu, Ann, David, Wang, Jeffrey, Prabhu, Sunil
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 03.04.2020
Subjects
chemoprevention
efficacy
nanotechnology
Pharmacology
relapse
targeted delivery
nanotechnology
targeted delivery
chemoprevention
relapse
efficacy
Online AccessGet full text

Cover

More Information
Summary:Cancer research in pursuit of better diagnostic and treatment modalities has seen great advances in recent years. However, the incidence rate of cancer is still very high. Almost 40% of women and men are diagnosed with cancer during their lifetime. Such high incidence has not only resulted in high mortality but also severely compromised patient lifestyles, and added a great socioeconomic burden. In view of this, chemoprevention has gained wide attention as a method to reduce cancer incidence and its relapse after treatment. Among various stems of chemoprevention research, nanotechnology-based chemoprevention approaches have established their potential to offer better efficacy and safety. This review summarizes recent advances in nanotechnology-based chemoprevention strategies for various cancers with emphasis on lung and bronchial cancer, colorectal, pancreatic, and breast cancer and highlights the unmet needs in this developing field towards successful clinical translation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Katrin Sak, NGO Praeventio, Estonia
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Reviewed by: Marcello Locatelli, Università degli Studi G. d'Annunzio Chieti e Pescara, Italy; Mariangela Garofalo, University of Padova, Italy
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2020.00323